United States Patent 6,290,961: Claims, Strength of Coverage, and US Patent Landscape for BoNT/B in Cervical Dystonia

US Patent 6,290,961 claims methods for treating cervical dystonia with botulinum toxin type B (BoNT/B). The claim set is broad on “time and conditions” and “effective amount,” while it narrows in dependent claims to intramuscular injection and to high BoNT/B dosing thresholds (at least about 50 units; at least about 1,000 units), plus specific onset timing (symptom alleviation within about 1 to about 7 days). Independent claim 1 is the core coverage grant; claims 2-6 add delivery and dose parameters; claims 7-8 define outcome metrics (abnormal head position; neck pain).

This profile matters because most cervical dystonia differentiation among BoNT products turns on: (1) injection route and muscles, (2) dose units and unit normalization across toxin brands, (3) onset window and clinical endpoint definitions, and (4) patient selection. US 6,290,961’s dependent claim architecture makes those distinctions legally material. It also creates infringement traps for would-be entrants that use different toxin types, different administration protocols, different dosing ranges, or dosing unit scales that do not map cleanly onto “units of botulinum toxin type B.”

What does US 6,290,961 actually claim?

Claim scope map

Below is a claim-by-claim distillation of the legally operative limitations you would test in freedom-to-operate and infringement analysis.

Claim	Key limitations (legally operative)	Coverage type
1	Administer an “effective amount” of BoNT/B to a human patient “under time and conditions” to treat cervical dystonia	Broad method claim; protocol is left flexible except for “time and conditions” and “effective amount”
2	Claim 1 wherein BoNT/B is administered by intramuscular injection	Narrows route to IM
3	Claim 1 wherein alleviation occurs within about 1 day to about 7 days	Adds a timing window
4	Claim 1 wherein at least about 50 units of BoNT/B are administered	Adds a low dosing threshold
5	Claim 1 wherein at least about 1,000 units of BoNT/B are administered	Adds a high dosing threshold
6	Claim 1 plus IM injection, alleviation within about 1-7 days, and at least about 1,000 units	Most specific dependent combination; strong if a practicing protocol matches all elements
7	Administer an effective amount of BoNT/B to reduce severity of abnormal head position	Outcome-defined functional limitation
8	Administer an effective amount of BoNT/B to reduce neck pain	Outcome-defined functional limitation

What is not claimed

The claim set does not specify:

particular injection muscles, injection pattern, or dilution volume,
BoNT/B formulation components (stabilizers, excipients) or reconstitution parameters,
patient selection criteria (severity score thresholds, prior therapy status, duration),
the number of injection sites and total injection volume,
a repeat dosing schedule beyond the initial “alleviation within 1-7 days” language in some dependent claims.

Legally, that absence increases interpretive breadth for claim 1 but keeps dependent claims vulnerable to protocol differences.

How strong is infringement risk for a “typical” cervical dystonia BoNT/B regimen?

Independent claim 1 sets the baseline risk

Claim 1 is satisfied if an accused clinician administers BoNT/B to treat cervical dystonia, and the dosing is an “effective amount” and is given “under time and conditions” to treat the disorder.

From a litigation perspective, “effective amount” is a familiar, fact-driven term. It generally turns on whether the regimen is clinically effective for cervical dystonia, not whether it matches a specific number. “Time and conditions” is also flexible; it can read broadly to encompass routine clinical practice and standard schedules.

Practical consequence: claim 1 can reach a wide range of BoNT/B practices, unless the accused regimen can be positioned outside “time and conditions” (rarely successful because clinical regimens are typically within the timeframe of treatment outcomes).

Dependent claims 2-6 create both proof opportunities and design-around points

Claim 2 (IM injection): If a product is delivered by a non-IM route, it can avoid claim 2. Most clinical cervical dystonia injections are IM into selected neck muscles, so claim 2 is often easy to satisfy.
Claim 3 (1-7 day alleviation): Many outcomes in cervical dystonia show improvement within the first week. If an accused regimen can document a later onset, it may be able to argue non-infringement of claim 3 and therefore claim 6.
Claims 4-6 (dose thresholds): The most actionable design-around lever is the dosing amount stated in the claims. A competitor that uses lower dosing, or a dosing scale that does not match “units of botulinum toxin type B” as used in the patent, can reduce risk for claims 4-6.
Claim 6 (combination): It is only infringed when all limitations are met simultaneously: IM injection, 1-7 day alleviation, and at least about 1,000 units.

Outcome-defined claims (7-8) are usually litigable by clinical correlation

Claims 7 and 8 tie infringement to reduction in “abnormal head position” and reduction in “neck pain,” respectively.

These limitations can be attacked as indefinite if “severity” is not objectively measurable in the claim language, but in practice they are typically tied to clinical outcome measures used in dystonia care.
They are also difficult to avoid if a BoNT/B regimen is accepted as clinically effective for these endpoints.

Net risk profile: claim 1 is the broadest threat; claims 2 and 7-8 are usually implicated by routine cervical dystonia care; claims 3-6 are more sensitive to dosing and onset documentation.

What defenses and invalidity theories are most plausible on this record?

No prosecution history, specification excerpts, or priority chain is provided in your prompt. Without that intrinsic evidence, the critical analysis below focuses on claim-text-driven attack surfaces that are commonly available in BoNT method patents.

1) Indefiniteness and claim construction pressure

“under time and conditions” in claim 1 is a phrase that invites construction disputes. A defendant can argue it is not tied to a measurable parameter in the claim language.
“effective amount” is broad, but courts often accept it when tied to a method of treating a disease. The strongest attack is usually when the patent does not provide a clear mapping between units and effect, but that requires specification review.

2) Anticipation and obviousness based on prior BoNT/B cervical dystonia knowledge

For anticipation/obviousness, the key is whether earlier references disclose:

BoNT/B administration to treat cervical dystonia,
IM injection for that indication,
clinical improvement timeframe,
and/or dose ranges expressed in “units” for BoNT/B.

Even if earlier art used BoNT/A or BoNT/E, the legal question becomes whether art teaches BoNT/B specifically and suggests using it for cervical dystonia in a way that meets the claim limitations.

3) Dose-unit issues: “about 1,000 units”

The patent’s high dose thresholds create a distinctive validity and infringement battleground:

If prior art uses materially different unit amounts or if units do not align across toxin brands and assay methods, “at least about 1,000 units” can become a nontrivial limitation.
If the relevant BoNT/B product in the market uses a different unit scale, defendants can argue the claim does not cover the accused regimen even if the clinical biological effect is similar.

This is a fact-intensive area but claim-text makes it central to both infringement and validity.

How does the claim architecture shape a competitor’s design-around strategy?

Below are the clearest “knock-out” strategies implied by the claim language.

Target limitation	Design-around lever	Effect on claims
IM route (claim 2, claim 6)	Non-IM delivery (rare for dystonia neck injections, but could include alternative targeting approaches)	Avoids claim 2 and therefore claim 6
Onset within 1-7 days (claim 3, claim 6)	Clinical approach with later measured alleviation window	Avoids claim 3 and therefore claim 6
Dose thresholds (claim 4-6)	Use < about 50 units or < about 1,000 units (or a dosing protocol that does not meet the unit mapping)	Avoids claims 4-6 depending on magnitude
Functional outcomes (claims 7-8)	Not applicable in normal practice if BoNT/B is effective for these endpoints	Harder to avoid if clinical effect is present

Most credible avoidance is dosing and documentation: lowering administered BoNT/B units below claimed thresholds is the cleanest route. The claim language also gives defendants room to argue “about” and unit mapping.

Where does this patent sit in the US BoNT landscape for cervical dystonia?

What matters in the broader US BoNT/B market

For business and R&D planning, the landscape typically splits by:

BoNT type (A vs B),
formulation/manufacturing (assay and unit definition),
clinical claims and label language (if any),
and patent families that focus on cervical dystonia treatment protocols.

US 6,290,961’s claims are aligned with the “product-independent method” model: it is not limited to one named commercial toxin product; it focuses on BoNT/B as the active and on generic clinical outcomes.

Why the 1,000-unit threshold is strategically important

High-unit method claims can be a moat if competitors use lower dosing as the standard-of-care. If industry practice moved toward lower total units with similar efficacy, the dependent high-dose claims narrow quickly. If practice historically used or approached those high dose levels, dependent claims strengthen.

In either case, the threshold becomes a commercial lever: dosing protocol selection can be a legal risk decision, not only a clinical decision.

What is the likely patentability profile and survivability risk?

From a patent-analytics standpoint, claims framed as a general “treat cervical dystonia with BoNT/B” method tend to be vulnerable to prior-art disclosure of the same indication with the same toxin type, especially when:

the art discloses a standard method of administering BoNT/B to dystonia,
the onset of benefit is routine in that art,
and dose ranges overlap the claimed “effective amount.”

The “damage” to patent survivability is usually concentrated in:

claim 1’s broad functional language,
and any claim that does not require a specific dosing algorithm or dosing schedule.

Conversely, survivability can improve when dependent claims tie to specific parameters (route, onset window, dose threshold) that are not disclosed together in a single prior reference, or when the evidence shows they were not obvious as a combination.

Key litigation/investor takeaways

Value drivers

Claim 1 breadth: A practicing BoNT/B cervical dystonia regimen can plausibly fall within “effective amount” and “time and conditions” without needing to hit numeric thresholds.
Dependent claim 6 specificity: If real-world protocols match IM injection plus 1-7 day alleviation plus at least 1,000 units, claim 6 becomes a strong, easy-to-prove infringement hook.

Main weaknesses

Potential prior disclosure of BoNT/B for cervical dystonia: Broad method claims that only require “treat with BoNT/B” often face anticipation or obviousness exposure.
Unit-dose mapping: “units” and “about 1,000 units” invite unit assay disputes and non-infringement arguments if the accused product uses different unit standards or if clinical dosing norms are lower.

Most actionable business decision

Competitors and investors should treat BoNT/B dosing and timing data as legal artifacts:

dosing magnitude relative to 50 and 1,000 “units,”
injection route documentation (IM),
and outcome timing (1-7 day window), because these parameters map directly to claims 2-6 and shape both infringement and validity posture.

Key Takeaways

US 6,290,961 claims BoNT/B treatment of cervical dystonia with broad coverage in claim 1 and narrower, parameterized risk in claims 2-6.
The most litigable dependent limitations are IM injection, onset within 1-7 days, and high-dose thresholds (>= about 50 units and >= about 1,000 units).
Claims 7-8 add functional outcome hooks (abnormal head position severity and neck pain reduction), which can be difficult to avoid if BoNT/B is clinically effective.
The single biggest commercial variable is whether an accused or planned regimen administers BoNT/B at or above the claimed unit thresholds and demonstrates improvement in the first week.

FAQs

Which claim is the strongest independent coverage point for US 6,290,961?
Claim 1, because it only requires administering an effective amount of BoNT/B under time and conditions to treat cervical dystonia.
What limitations most directly enable design-around strategies?
The dosing thresholds (claims 4-6) and the onset window (claims 3 and 6), because they are numeric and timeframe-bound in the claim language.
How critical is injection route to infringement risk?
Route is pivotal for claim 2 and claim 6 because they require intramuscular injection.
Do claims 7 and 8 require a specific clinical scoring system?
The claim language requires functional reduction of abnormal head position severity and neck pain, but it does not name a specific instrument; infringement typically turns on clinical outcome evidence.
What parameter should investors monitor when assessing freedom-to-operate for BoNT/B in cervical dystonia?
Total BoNT/B units administered and documented onset of symptom alleviation within 1-7 days.

References

[No sources were provided in the prompt to cite specific bibliographic or patent documents beyond the claim text you supplied.]

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Solstice Neurosciences, Llc	MYOBLOC	rimabotulinumtoxinb	Injection	103846	December 08, 2000	⤷ Start Trial	2020-01-24
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	May 07, 2001	⤷ Start Trial	2020-01-24
Genzyme Corporation	LEMTRADA	alemtuzumab	Injection	103948	November 14, 2014	⤷ Start Trial	2020-01-24
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	October 12, 2004	⤷ Start Trial	2020-01-24
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	9517904	⤷ Start Trial
United States of America	8557256	⤷ Start Trial
United States of America	8486886	⤷ Start Trial
United States of America	8216995	⤷ Start Trial
United States of America	8187612	⤷ Start Trial
United States of America	8052980	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Patent: 6,290,961

Summary for Patent: 6,290,961